 CNBC.com |
Pfizer's Torisel drug fails in a combination study
Reuters (Reuters) – Pfizer Inc said on Friday that a late-stage trial of its drug for renal cell cancer failed to meet its main goal when given in combination with Avastin, a drug made by Roche Holding AG. Pfizer's drug Torisel is approved as a single agent … Reuters Health News Summary Pfizer: Phase 3 Trial of Torisel for RCC Patients Fails to Meet Primary Endpoint Pfizer says Torisel-Avastin failed in cancer study |
SanDisk Ultra 64 GB MicroSDXC Class 10 UHS-1 Memor...
176 days in the top 100 
(4311) 
143 days in the top 100 
(2041) 
(2060) 
Comments on this entry are closed.